Methysergide (Hydrogen Maleate)

Methysergide (Hydrogen Maleate) is one of the most potent serotonin antagonist available. itthe N-methyl derivative of methylergonovine, a semisynthetic ergot alkaloid. Chemically itidentified as 9,10-Dihydro-N-[1-(hydroxymethyl)propyl]-1, 6-dimethylergoline-8 β-carboxamide maleate. However, its oxytocic activity is much weaker, and is not employed as an oxytocic. itgiven by mouth and its principal therapeutic use is in the treatment and prophylaxis of migraine headache, for which the drug is quite effective, but it is of very little use during an acute attack.

Brands
Adult Dose
Dose: 0.019 to 0.038 mg/kg
Single Dose: 0.029 (0.0285)
Frequency: 8 hourly
Route: PO
Instructions: -
Neonatal
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Paedriatic
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Characteristics
. It is of Semi Synthetic origin and belongs to Ergot Alkaloid. It belongs to 5HT-2 antagonist pharmacological group on the basis of mechanism of action and also classified in Analgesics and Anti-inflammatory Agents and Ergot Alkaloid pharmacological group.The Molecular Weight of Methysergide (Hydrogen Maleate) is 469.50. Its pKa is 16.
Contraindications
Methysergide (Hydrogen Maleate) is contraindicated in conditions like Peripheral vascular disease,Heart disease,Impaired renal function,Collagen disease,Cardiac disease,Urinary tract disorder,Cachexia,Sepsis.
Effects
The severe or irreversible adverse effects of Methysergide (Hydrogen Maleate), which give rise to further complications include Eosinophilia, Eosinophilia, Neutropenia, Peripheral vascular disease, Cardiac disease.Methysergide (Hydrogen Maleate) produces potentially life-threatening effects which include Dyspnea, Retroperitoneal fibrosis, Pleuropulmonary fibrosis. which are responsible for the discontinuation of Methysergide (Hydrogen Maleate) therapy.The signs and symptoms that are produced after the acute overdosage of Methysergide (Hydrogen Maleate) include Tachycardia, Headache, Mydriasis, Agitation.The symptomatic adverse reactions produced by Methysergide (Hydrogen Maleate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Vomiting, Restlessness, Skin reactions, Insomnia, Abdominal pain, VertigoX, Hallucination, Heart burn, Light headedness, Edema, Euphoria, Vasoconstriction, Numbness & painful extremities.
Indications
'Methysergide (Hydrogen Maleate) is primarily indicated in conditions like Diarrhea associated with carcinoid syndrome, Horton''s syndrome, Migraine, Migraine prophylaxis.'
Interactions
Methysergide (Hydrogen Maleate) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAmprenavirIncreased risk of ergotism when Amprenavir given with Methysergide. ADVICE: Avoid concomitant use.MajorErgotamine (Tartrate)arterial occlusion has been reported in patients given methysergide witha a high parenteral dosage of ergotamine for cluster headache.coadministration should be avoidedNaratriptanConcurrent use have been reported to cause prolonged vasospastic reactions. Concurrent use is not recommended. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Tab Store Below 40°C. Protect from Sunlight and Moisture.
Warnings
Methylsergide should be used with caution (if contains tartrazine) in patients with aspirin hypersensitivity because it may cause allergic type reaction (including bronchial asthma). The drug should not be used during pregnancy and lactation. It should never be used in the patient with renal impairment.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.